Paper Details

  1. Home
  2. Paper Details

High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.

Author: BogdanovicAndrija, DyagilIrina, FongDominic, GastlGuenther, GerchevaLiana, GoranovStefan, GriniuteRasa, GriskeviciusLaimonas, KwakkelsteinMarthin, LejnieceSandra, LionThomas, MasliakZvenyslava, OuchevaRadka, PetzerAndreas L, PeytchevDontcho, RancatiFrancesca, StojanovicAleksandar, TzvetkovNikolay, UlmerHanno, WolfDominik

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

High-dose imatinib therapy (800 mg/day for 6 months followed by 400 mg/day) resulted in faster and higher rates of cytogenetic and molecular responses compared to standard-dose imatinib (400 mg/day) in patients with pre-treated chronic myeloid leukemia.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Imatinib 400 mg/day is the standard treatment for patients with chronic phase chronic myeloid leukemia. Recent reports suggested higher and more rapid cytogenetic and molecular responses with higher doses of imatinib. DESIGN AND METHODS: In this prospective international, multicenter ph...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878787/

データ提供：米国国立医学図書館（NLM）

The Role of High-Dose Imatinib in Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a serious blood cancer, often likened to a relentless desert storm that disrupts the body's normal processes. This research, like a dedicated oncologist seeking new treatments, explores the potential of high-dose imatinib, a targeted therapy for CML, in patients who have already received prior treatment. The authors examine the efficacy and safety of this approach, seeking to improve outcomes for patients with CML. This study highlights the potential of high-dose imatinib as a valuable tool in managing this challenging disease.

The Potential of High-Dose Imatinib for CML

This research unveils the potential benefits of high-dose imatinib in treating CML. The study's findings, like a well-stocked caravan, demonstrate the effectiveness of this approach in achieving cytogenetic and molecular remissions, offering a promising avenue for improving outcomes for patients with CML. The authors emphasize the importance of careful monitoring for potential side effects, ensuring the safe and effective use of this treatment.

Navigating the Desert of CML Treatment

CML can be a challenging disease, but this research offers hope for a more effective treatment landscape. The study's findings, like a refreshing oasis in the desert, suggest that high-dose imatinib can be a valuable tool for achieving remissions and improving quality of life for patients with CML. This research encourages further research to optimize this approach and explore other potential strategies for managing this disease.

Dr.Camel's Conclusion

This research highlights the potential of high-dose imatinib in treating CML, offering a beacon of hope in the challenging desert of cancer treatment. The study's findings, like a well-planned caravan journey, suggest that this approach can improve outcomes for patients with CML, but emphasize the need for careful monitoring and continued research to optimize its use.

Date :
  1. Date Completed 2011-08-08
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

20145273

DOI: Digital Object Identifier

PMC2878787

Related Literature

Article Analysis
・Effective treatment of chronic myeloid leukemia
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.